BRCA1 and ovarian carcinoma: PARPi are efficacious in HGSOCs with defective DNA repair by homologous recombination (HR) due to mutation in the breast and ovarian cancer predisposition genes BRCA1 or BRCA2 (BRCA1/2)1.